Coptisine

CAS : 3486-66-6

Ref. TM-T5S0053

Informations sur le produit

• Nom: Coptisine
• Synonymes: Coptisin, 6,7-Dihydrobis[1,3]benzodioxolo[5,6-a:4′,5′-g]quinolizinium, Alkaloid A, from Coptisgroenlandica, Alkaloid A, fromCoptis groenlandica, Berbinium,7,8,13,13a-tetradehydro-2,3:9,10-bis(methylenedioxy)-, Bis[1,3]benzodioxolo[5,6-a:4',5'-g]quinolizinium,6,7-dihydro-, Bis[1,3]benzodioxolo[5,6-a:4′,5′-g]quinolizinium, 6,7-dihydro-, Yhl Ii
• CAS: 3486-66-6

Description

1. Coptisine (Coptisin) treatment increases cell viability based on its reversal effect on the enhanced activity of Indoleamine 2, 3-dioxygenase . 2. Coptisine treats myocardial I/R likely through suppressing myocardial apoptosis and inflammation by inhibiting the Rho/ROCK pathway. 3. Coptisine is a potential anti-osteosarcoma drug candidate, via exerting a strong anti-osteosarcoma effect with very low toxicity . 4. Coptisine with a high dosage could inhibit cholesterol synthesis via suppressing the HMGCR expression and promoting the use and excretion of cholesterol via up-regulating LDLR and CYP7A1 expression. 5. Coptisine suppresses adhesion, migration and invasion of MDA-MB-231 breast cancer cells in vitro, the down-regulation of MMP-9 in combination with the increase of TIMP-1 possibly contributing to the anti-metastatic function for breast cancer.

• Marque: Targetmol

Propriétés chimiques

• Masse moléculaire: 320.32
• Formule: C₁₉H₁₄NO₄
• Degré de pureté: 99.91%
• Couleur/Forme: Solid